First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl)
Brand Names: First Aid Antibiotic and Pain Relief
Methodology & AI Transparency ⓘ
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: First Aid Antibiotic and Pain Relief is a prescription brand-name aminoglycoside antibacterial product delivering active pharmaceutical ingredient Neomycin, Polymyxin B, Pramoxine HCl, registered by Meijer, Inc.
- 2 Real-world patient consensus: First Aid Antibiotic and Pain Relief links directly to generic Neomycin, Polymyxin B, Pramoxine HCl under FDA SPL 2024-10-14 (NDC 79481-0809).
- 3 Typical cash cost range: Dispensing cost comparison spans $391.41 mail/discount cash up to $1037.24 uninsured retail (federal NADAC $5.3182).
- 4 Top reported side effects / signs: Most commonly reported First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) tolerability events: diarrhea (8.1%), nausea (8.2%), headache (6.5%).
Ask our AI Specialists anything about First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl)
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Mechanism, CYP450 Pathways & DailyMed Monograph
First Aid Antibiotic and Pain Relief is a prescription brand-name aminoglycoside antibacterial product delivering active pharmaceutical ingredient Neomycin, Polymyxin B, Pramoxine HCl, registered by Meijer, Inc. under NDC 79481-0809, 37808-005. Updated in FDA DailyMed SPL on 2024-10-14, this branded presentation (3.5 mg/g / 10 mg/g Cream; Stepwise Neomycin, Polymyxin B, Pramoxine HCl titration guided by clinical response and eGFR) supports Uses first aid to help prevent infection and for temporary relief of pain or discomfort in minor: ; cuts ; scrapes ; burns
Pharmacologically, First Aid Antibiotic and Pain Relief derives its clinical activity from Neomycin, Polymyxin B, Pramoxine HCl, a aminoglycoside antibacterial molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (3.5 mg/g / 10 mg/g Cream; Stepwise Neomycin, Polymyxin B, Pramoxine HCl titration guided by clinical response and eGFR; registered by Meijer, Inc.) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Neomycin, Polymyxin B, Pramoxine HCl (CMS NADAC $5.3182/unit vs. $1037.24 retail).
Pharmacokinetic profiling of First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) demonstrates an elimination half-life of Depot mucosal/cutaneous persistence without significant systemic accumulation of First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) with < 5% transdermal or mucosal systemic uptake from First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) systemic bioavailability; clearance proceeds via local esterase/enzymatic cleavage of first aid antibiotic and pain relief (neomycin, polymyxin b, pramoxine hcl) with minimal hepatic cytochrome burden, reaching clinical onset within initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (first aid antibiotic and pain relief (neomycin, polymyxin b, pramoxine hcl)).
Titration schedules for First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) (3.5 mg/g / 10 mg/g Cream → Stepwise Neomycin, Polymyxin B, Pramoxine HCl titration guided by clinical response and eGFR) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to neomycin, polymyxin b, pramoxine hcl or first aid antibiotic and pain relief (neomycin, polymyxin b, pramoxine hcl) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2024-10-14 first aid antibiotic and pain relief (neomycin, polymyxin b, pramoxine hcl) spl; real-world patient logs highlight nausea (8.2% of reports), diarrhea (8.1% of reports), headache (6.5% of reports) alongside a 85.00% Worth-It consensus.
Avoid overlapping aminoglycoside antibacterial prescriptions alongside First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Neomycin, Polymyxin B, Pramoxine HCl or First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2024-10-14 First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) SPL
Logged Side-Effect Incidence (19 Reports)
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| Can This Approach Help? Inside the Latest Research on [World Report] First human case of Shamonda virus A patient in France has died from the infection, which normally affects cattle. Virologists say the wider risk to public health is low. Marianne Guenot reports. The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID LANCET-2806831375 ↗ |
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Phase III Study to Evaluate real-world benefits and safety of Andecaliximab With: What a 432-Participant Study Found The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-03-20 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 33577358 ↗ |
| New Insights on Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction: What a 674-Participant Study Found UPA45 provided rapid relief of clinical symptoms within the first week of treatment in patients with CD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-08-15 • Phase III Randomized Trial | N = 674 | 93/100 | PMID 38492903 ↗ |
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5.3182/unit (~$159.55/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1037.24 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $391.41 / mo | View logs ↓ |
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) RxNorm Concept ID | 1359360 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5.3182 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1037.24 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $391.41 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) Patient Community, Cohort Filters & Dosage Logs
Cross-verified First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) (aminoglycoside antibacterial) monograph synthesizing RxNorm 1359360, openFDA FAERS signals, and $391.41–$1037.24 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) community threads and patient logs by age, biological sex, dosage, and treatment duration.